Policy & Regulation
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
17 November 2026 -

Norwegian biotech company Oncoinvent ASA (OSE:ONCIN) on Tuesday reported favourable safety and tolerability results from the first interim safety analysis of its randomised phase 2 trial evaluating Radspherin in patients with advanced ovarian cancer and peritoneal metastases.

As of 30 October 2026, 74 patients had been randomised, with 56 primary ovarian cancer patients included in the safety analysis. Of these, 40 received a single 7 MBq intraperitoneal dose of Radspherin following surgery alongside standard care, while 16 received standard care alone.

No serious adverse events were considered related to Radspherin, and no deaths or adverse events leading to treatment discontinuation were reported. The incidence of treatment-emergent adverse events was similar across both groups, with most events in the Radspherin arm considered unrelated to treatment.

The Independent Data Monitoring Committee reviewed the unblinded safety data on 13 November 2026 and recommended that the trial continue without modifications.

Recruitment is expected to be completed in the first half of 2027, with the interim efficacy results scheduled for April 2027 and expected to include close to all randomised patients.

Login
Username:

Password: